Sofamor tops $100 million this quarter:
This article was originally published in Clinica
Memphis, Tennessee-based Sofamor Danek's three-month sales topped $100 million for the first time in the company's history. The orthopaedics company says domestic sales growth was led mainly by an increase in the number of instrumented spinal fusions. During the third quarter, the FDA issued a final rule reclassifying pedicle screw systems, after over three years of review. The company says the ruling is a "real victory" for the spinal implant industry and should hasten the end of Sofamor's pedicle screw-related litigation.
You may also be interested in...
India’s Sun Pharma has been denied leave to appeal against a US court decision rejecting the company’s bid for dismissal of a multi-district antitrust lawsuit.
Former Sandoz executive Hector Armando Kellum has admitted involvement in a US generic price-fixing conspiracy, the US Department of Justice has announced.
The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.